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Abstract
A strategy to replace the ethylamine side chain of 2,5-dimethoxy-4-iodoamphetamine (DOI, 1a), and 2,5-dimethoxy-4-bromo-
amphetamine (DOB, 1b) with a cyclopropylamine moiety was successful in leading to compounds with high affinity at the 5-HT2
family of receptors; and the more potent stereoisomer of the cyclopropane analogues had the expected (−)-(1R,2S)-configuration.
Screening for affinity at various serotonin receptor subtypes, however, revealed that the cyclopropane congeners also had increased
affinity at several sites in addition to the 5-HT2A and 5-HT2B receptors. Therefore, at appropriate doses – although (−)-4 and (−)-5
may be useful as tools to probe 5-HT2 receptor function – one would need to be mindful that their selectivity for 5-HT2A receptors
is somewhat less than for DOI itself.
Introduction
Among the molecules that have proven very valuable to neuro-
scientists studying brain serotonin systems is the substituted
phenethylamine derivative 2,5-dimethoxy-4-iodoamphetamine
(DOI, 1a, Figure 1), a potent but nonspecific agonist ligand for
serotonin 5-HT2A and 5-HT2C receptors. It is relatively inex-
pensive and has been widely used throughout the neuroscience
community to study behaviors mediated by 5-HT2 family recep-
tors. Indeed, as of June 12, 2012, a PubMed search of the terms
DOI + 5-HT2 yielded 577 hits, spanning from 1984 to the
present. Despite the fact that no significant abuse of DOI has
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Figure 1: Structures of well-known serotonin 5-HT2A agonists 1a,b, 2, and 3, and compounds 4 and 5 reported in this paper.
been reported, this substance has been scheduled in a number of
countries and has been considered for scheduling by the U.S.
Drug Enforcement Administration (DEA). Classification as a
controlled substance will be a setback to the neuroscience
community because it effectively prevents experiments in any
laboratory that does not have a proper license for the use of
DOI. To illustrate this point, a related compound – bromo
congener 1b (DOB) – presently is a controlled substance and
only 52 hits for DOB + 5-HT2 were obtained from PubMed,
compared with 577 for DOI over the same period of time.
Anticipating the potential need for a substance to replace DOI
as a research tool, we sought to identify a molecule that might
have pharmacological properties which are identical, or at least
very similar to those of 1a. We had previously characterized the
cyclopropane analogue of a hallucinogenic amphetamine known
as DOM (2) and had shown that 3 (DMCPA) had high potency
both in vitro and in vivo [1-3]. We thus considered whether the
cyclopropane analogues 4 and 5 might be useful research tools.
Accordingly, this report details the synthesis of racemic trans-
1-(2,5-dimethoxy-4-iodophenyl)-2-aminocyclopropane (4) and
its bromo homolog 5, the resolution of 4 into its (−)-(1R,2S)-
enantiomer, as well as the resolution of the cyclopropane
carboxylic acid precursor and subsequent bromination to
provide both enantiomers of 5.
Results and Discussion
Racemic 4 and 5 were compared in radioligand competition
assays against radiolabeled antagonists defined at the human
5-HT2A and 5-HT2C receptors and compared with racemic 1a
and 1b. The results are shown in Table 1. As can be seen, the
cyclopropane analogues 4 and 5 showed affinities for the
5-HT2A receptor 5–6-fold greater than 1a and 1b. Affinities at
the 5-HT2C receptor were about two-fold higher than for 1a and
1b.
The more potent (−)-enantiomers were then tested for func-
tional potency using a calcium release assay. The EC50 values
and maximal effect at the 5-HT2A receptor were virtually iden-
tical for 1a and 4, and for 1b and 5 (Table 2).
Table 1: Affinity values (Ki in nM) at human 5-HT2A and 5-HT2C recep-







(±)-1a 7.6 ± 0.9 35 ± 6
(±)-1b 8.9 ± 0.5 31 ± 5
(±)-4 1.5 ± 0.1 17 ± 3
(±)-5 1.4 ± 0.3 7.5 ± 1.1
Table 2: Potency and percent max values for calcium release at
5-HT2A and 5-HT2C receptors. All values represent mean and SEM







(−)-1a 3.3 ± 0.7 87 ± 1 8.7 ± 0.2 50 ± 5
(−)-1b 5.8 ± 1.3 75 ± 7 28 ± 4 59 ± 7
(−)-4 2.0 ± 0.3 89 ± 4 21 ± 4 63 ± 6
(−)-5 6.3 ± 1.6 76 ± 10 32 ± 8 77 ± 6
At the 5-HT2C receptor 1a was the most potent, with an EC50
that was about three times lower than for 1b, 4, or 5. In func-
tional assays, therefore, the cyclopropane analogues 4 and 5
compared to 1a or 1b appeared as potent and had a similar
degree of maximal stimulation at each of the respective 5-HT2
receptors.
We then carried out a broader screen of 4 and 5 for affinities at
a range of other 5-HT receptor isoforms (Table 3). Their affini-
ties at other 5-HT receptors, however, were higher than for 1a.
In particular, the introduction of the cyclopropane appears to
increase significantly affinities at the 5-HT1A, 5HT1B, and
5-HT1D receptors. In that regard, although (−)-4 and (−)-5 have
affinities at the 5-HT2A receptor somewhat higher than 1a, their
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Table 3: Affinity values (Ki in nM) at selected serotonin receptor isoforms.
Cmpd 5-HT1A 5-HT1B 5-HT1D 5-HT1E 5-HT2A 5-HT2B 5-HT2C 5-HT6 5-HT7
(±)-1a <50%a <50%a <50%a 1090 9 3 19 1380 850
(±)-4 410 290 535 1660 9 10 17 100 580
(−)-4 150 230 90 1380 2.4 6 7.4 70 260
(+)-5 210 <50%a <50%a <50%a 540 20 130 NA 170
(−)-5 220 375 390 890 3 4 9 45 120
a<50% displacement at 10−6 M.
Scheme 1: Synthesis of arylcyclopropane carboxylic acids from the corresponding cinnamic acids, followed by halogenation.
selectivity over the 5-HT1A receptor is less than 100-fold. As
shown in Table 1, both 4 and 5 are extremely potent ligands in
vitro. Furthermore, as anticipated, it was the (−)-enantiomers
that proved to have highest affinity. We included (+)-5 in
Table 3 simply to illustrate the difference in affinity between
the two enantiomers. We assume that the final compounds have
the (−)-(1R,2S) and (+)-(1S,2R) absolute configurations based
on our earlier work establishing the absolute configuration of 3
[2], and the fact that substitutions at the 4-position of the
aromatic ring in chiral substituted amphetamines do not change
the sign of optical rotation [4]. The biological data are consis-
tent with those configuration assignments.
Chemistry
We reasoned that a palladium-mediated cyclopropanation of the
corresponding cinnamic acids would provide the required
cyclopropanecarboxylic acid (Scheme 1); which could be
readily converted to the amine by a Curtius type rearrangement
(Scheme 2). In our previous synthesis [2] we had employed an
N-carbobenzoxy intermediate, followed by catalytic debenzyla-
tion over Pd(C); but those conditions would lead to dehalogena-
tion in the present series, so we instead employed acid-
catalyzed removal of a BOC protecting group (Scheme 2).
Thus, we first prepared 2-(2,5-dimethoxyphenyl)cyclo-
propanecarboxylic acid methyl ester (7) from the corres-
ponding cinnamic ester 6 [5], followed by I2/AgNO3 iodination
(Scheme 1), and base hydrolysis of the resulting ester to provide
iodo acid 10a. Hydrolysis of ester 7 followed by bromination of
acid 9 using Br2-dioxane complex gave a good yield of bromo
acid 10b.
These acids were readily converted to their isocyanates using
the Weinstock modification of the Curtius rearrangement [6].
Those isocyanates were heated with tert-butanol to afford the
corresponding carbamates 11a and 11b (Scheme 2). A brief
treatment of these with 3 M HCl at 45 °C cleanly affected
N-deprotection and afforded the desired final amines 4 and 5.
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Scheme 2: Conversion of arylcyclopropane carboxylic acids 10a,b to the amines 4 and 5, and chemical resolution of 4 into its enantiomers.
Scheme 3: Chemical resolution of arylcyclopropane carboxylic acid 9 followed by bromination.
The stereochemistry of the more potent enantiomer of DOI is
(−)-(R) [7], and of 3 is (−)-(1R,2S) [2]. We therefore undertook
the resolution of the enantiomers of DOI by fractional crystal-
lization of the diastereomeric salts prepared with di-O,O-
benzoyltartaric acid. Unfortunately, we discovered that heating
solutions of the dibenzoyltartrate salt of 4 in EtOH or iPrOH led
to nearly complete decomposition, presumably through a cyclo-
propane ring-opening pathway. The apparent need to recrystal-
lize the O,O-dibenzoyltartrate salts from a nonprotic solvent led
us to employ warm acetone, which proved satisfactory. The
resolution went well, achieving constant optical rotation after
only three crystallizations. The salt was converted to the free
base, which was dissolved in dry Et2O, followed by addition of
the stoichiometric amount of ethereal HCl. The salt precipitated
out of solution and could be used directly for pharmacological
experiments. Attempts to recrystallize the HCl salt from protic
solvents also led to nearly complete decomposition, although
salts of bromo compound 5 appeared somewhat more stable.
We then followed a more efficient divergent approach to obtain
the enantiomers of 5 that employed resolution of the cyclo-
propane carboxylic acid, followed by bromination, and then
conversion to the cyclopropylamine (Scheme 3). We are aware
that the use of chiral auxiliaries in the cyclopropanation step
could directly afford the chiral cyclopropane acids [8], but time
and resources did not allow us to pursue that approach.
Conclusion
In conclusion, our strategy to replace the ethylamine side chain
of 1a (or 1b) with a cyclopropylamine moiety was successful in
leading to compounds with high affinity at the 5-HT2 family of
receptors; and the more potent stereoisomer of the cyclo-
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propane analogues had the expected (−)-1R,2S-configuration.
However, at appropriate doses, although (−)-4 and (−)-5 may be
useful as tools to probe 5-HT2 receptor function, one would also
need to be mindful that their selectivity for 5-HT2A over
5-HT1A is only about 70-fold.
The most efficient approach appears to be the synthesis of the
chiral cyclopropane carboxylic acids, followed by derivatiza-
tion at the 4-position. This approach would be most appealing if
a chiral auxiliary was used in the cyclopropanation step [8]. We
also note that compound 4 was less stable than 5 under recrys-
tallization conditions, an instability we did not observe during
our earlier work with 3. We have observed even greater insta-
bility in 2-(indol-3-yl)cyclopropylamines [8,9], suggesting that
electron “excessive” π-systems, or the ability to “donate” elec-
trons through resonance (i.e. Br and I), leads to cyclopropane
ring instability in 2-arylcyclopropylamines.
Supporting Information
Supporting Information File 1
Experimental details for all new compounds as well as the
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